NASDAQ · Biotechnology

GT Biopharma, Inc. (GTBP) Stock

$6.68 +12.08% NASDAQ: GTBP Healthcare

Valuation

MetricValue
Price$6.68
Market Cap$8.43M
P/E Ratio-0.06
P/B Ratio2.65
P/S Ratio0.00
EPS (TTM)$-6.25
52-Week High$34.25
52-Week Low$4.91
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-443.08%
ROA-381.53%
ROCE-457.75%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.00

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-58.0M$-21.0M$-14.0M$-14.0M$-12.0M
Net Profit$-58.0M$-21.0M$-8.0M$-13.0M$-28.0M
EPS$-51.50$-16.50$-141.00$-173.50$-156.25
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$32.0M$17.0M$14.0M$4.0M$8.0M
Total Liabilities$10.0M$5.0M$7.0M$6.0M$2.0M
Cash$9.0M$6.0M$1.0M$4.0M$7.0M
Borrowings$0$0$0$0$0

Latest News

GT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological Initiatives GlobeNewswire · Jun 1, 2026 EXCLUSIVE: GT Biopharma Sees Faster Discovery, Productivity Following AI Technology Rollout Benzinga · Jun 1, 2026 GT Biopharma Reports First Quarter 2026 Financial Results GlobeNewswire · May 15, 2026 GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors GlobeNewswire · May 14, 2026 EXCLUSIVE: GT Biopharma Begins Testing Of Lead Solid Tumor Drug Candidate Across Multiple Cancer Types Benzinga · May 14, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-16.0M$-15.0M$-9.0M$-13.0M$-13.0M
Investing Cash Flow$-23.0M$12.0M$-2.0M$13.0M$0
Financing Cash Flow$16.0M$0$0$0$0
Net Cash Flow$4.0M$-3.0M$-5.0M$3.0M$3.0M
Free Cash Flow$-16.0M$-15.0M$-9.0M$-13.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.13
FCF Yield-187.37%
Quick Ratio2.61
Interest Coverage-128.64
Return 1Y-82.48%
Return 3Y-96.50%
Return 5Y-99.90%

Ownership

Insiders Held5.81%
Institutions Held4.08%
Institutions Float Held4.33%
Institutional HolderSharesReport Date
Vanguard Capital Management LLC451,8752026-03-31
Geode Capital Management, LLC294,4592026-03-31
Vanguard Fiduciary Trust Co225,9382026-03-31
Everhart Financial Group, Inc.100,0002026-06-30
Arax Advisory Partners93,6272026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $336.64 -1.11% 38.93 $4.94T 0.32%
MSFTMicrosoft Corporation $535.07 +2.38% 28.68 $3.97T 0.76%
GOOGLAlphabet Inc. $351.66 +0.97% 16.94 $4.26T 0.26%
AMZNAmazon.com, Inc. $262.43 +3.29% 19.82 $2.82T 0.00%
METAMeta Platforms, Inc. $718.67 -0.31% 27.93 $1.83T 0.28%

About GT Biopharma, Inc.

GT Biopharma, Inc. is led by CEO Michael Martin Breen, employs 1 people, headquartered in US, publicly traded since 2018.

GT Biopharma, Inc. (GTBP) stock trades at $6.68 with a market capitalization of $8.43M. The stock is valued at a price-to-earnings (P/E) ratio of -0.06, price-to-book of 2.65, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $4.91 and $34.25, and currently trades 80.5% below its 52-week high.

On profitability, GT Biopharma, Inc. generates a return on equity (ROE) of -443.08%, return on capital employed of -457.75%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides